Previous 10 | Next 10 |
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on ...
CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
Shares of Mersana Therapeutics (MRSN) have lost two-thirds of their value since its IPO was priced at $15 in June of 2017. So far, in 2019, shares have risen by over 20%, as interest comes back to the name due to intriguing preliminary data for its lead program. Given that it has a poster ...
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today annou...
Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Conference Call May 09, 2019, 08:00 AM ET Company Participants Sarah Carmody - IR and Corporate Communications Anna Protopapas - CEO Tim Lowinger - Chief Scientific Officer Dave Spellman - CFO Eva Jack - Chief Business Office...
Mersana Therapeutics (NASDAQ: MRSN ): Q1 EPS of $0.70 may not be comparable to consensus of -$0.07. More news on: Mersana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Emerging Safety and Tolerability Profile Supports Advancement of Program; Plans for Expansion Cohort Initiation on Track Company Plans to Present Interim Data from the Ongoing XMT-1536 Dose Escalation Study at the ASCO 2019 Annual Meeting Ended First Quarter 2019 with $137 ...
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...